[go: up one dir, main page]

CY1121750T1 - Cot διαμορφωτες και μεθοδοι χρησης αυτων - Google Patents

Cot διαμορφωτες και μεθοδοι χρησης αυτων

Info

Publication number
CY1121750T1
CY1121750T1 CY20191100535T CY191100535T CY1121750T1 CY 1121750 T1 CY1121750 T1 CY 1121750T1 CY 20191100535 T CY20191100535 T CY 20191100535T CY 191100535 T CY191100535 T CY 191100535T CY 1121750 T1 CY1121750 T1 CY 1121750T1
Authority
CY
Cyprus
Prior art keywords
cot
methods
modifiers
modulators
production
Prior art date
Application number
CY20191100535T
Other languages
English (en)
Inventor
Elizabeth M. Bacon
Gayatri BALAN
Christopher T. Clark
Jeromy J. Cottell
Musong Kim
Thorsten A. Kirschberg
John O. Link
Gary Phillips
Scott D. Schroeder
Neil H. SQUIRES
Kirk L. Stevens
James G. TAYLOR
William J. Watkins
Nathan E. Wright
Sheila M. Zipfel
Chien-Hung Chou
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1121750T1 publication Critical patent/CY1121750T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)

Abstract

Η παρούσα αποκάλυψη σχετίζεται γενικά με διαμορφωτές της Cot (cancer Osaka thyroid) και με μεθόδους χρήσης και παραγωγής αυτών.
CY20191100535T 2015-07-06 2019-05-20 Cot διαμορφωτες και μεθοδοι χρησης αυτων CY1121750T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17
PCT/US2016/040520 WO2017007689A1 (en) 2015-07-06 2016-06-30 Cot modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1121750T1 true CY1121750T1 (el) 2020-07-31

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100535T CY1121750T1 (el) 2015-07-06 2019-05-20 Cot διαμορφωτες και μεθοδοι χρησης αυτων

Country Status (41)

Country Link
US (7) US20170008905A1 (el)
EP (3) EP3191470B1 (el)
JP (6) JP6430060B2 (el)
KR (5) KR20240008398A (el)
CN (4) CN109879859B (el)
AU (5) AU2016290820B2 (el)
BR (1) BR102016015656B1 (el)
CA (1) CA2971640C (el)
CL (1) CL2017003356A1 (el)
CO (1) CO2017013351A2 (el)
CR (1) CR20170599A (el)
CU (1) CU20170172A7 (el)
CY (1) CY1121750T1 (el)
DK (1) DK3191470T3 (el)
DO (1) DOP2017000311A (el)
EA (1) EA036788B1 (el)
EC (1) ECSP17084635A (el)
ES (2) ES2872076T3 (el)
HR (1) HRP20190853T1 (el)
HU (1) HUE043310T2 (el)
IL (4) IL274568B (el)
LT (1) LT3191470T (el)
MA (1) MA39422B1 (el)
ME (1) ME03425B (el)
MX (1) MX370984B (el)
MY (1) MY196173A (el)
NZ (2) NZ750707A (el)
PE (1) PE20180462A1 (el)
PH (2) PH12018500031A1 (el)
PL (2) PL3456717T3 (el)
PT (2) PT3191470T (el)
RS (1) RS58639B1 (el)
SA (1) SA517381350B1 (el)
SG (1) SG11201702041PA (el)
SI (2) SI3456717T1 (el)
SM (1) SMT201900244T1 (el)
SV (1) SV2017005605A (el)
TW (3) TWI634112B (el)
UA (1) UA123010C2 (el)
UY (1) UY36771A (el)
WO (1) WO2017007689A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
JP6525362B2 (ja) 2015-07-06 2019-06-05 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔモジュレーターとしての６−アミノ−キノリン−３−カルボニトリル
ME03425B (me) 2015-07-06 2020-01-20 Gilead Sciences Inc Cot modulatori i postupci za njihovu upotrebu
WO2018005435A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
ES2954514T3 (es) 2016-08-19 2023-11-22 Gilead Sciences Inc Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del VIH
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
US20200275661A1 (en) * 2017-09-26 2020-09-03 Nippon Soda Co., Ltd. Quinoline compound, and agricultural and horticultural fungicide
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
EP4253366A3 (en) 2018-02-16 2023-11-29 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
TW202425967A (zh) 2018-07-16 2024-07-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TW202235416A (zh) * 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
HRP20240297T1 (hr) 2019-08-29 2024-05-10 Idorsia Pharmaceuticals Ltd Derivati alfa-d-galaktopiranozida
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
KR20220161438A (ko) * 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
KR20220160645A (ko) 2020-04-02 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 저해제 화합물의 제조 방법
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US20240109930A1 (en) 2021-03-03 2024-04-04 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
TW202304435A (zh) * 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
US20240285646A1 (en) * 2021-06-11 2024-08-29 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AU2022399845A1 (en) 2021-12-03 2024-05-23 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2024245157A1 (zh) * 2023-05-30 2024-12-05 浙江星浩澎博医药有限公司 氮杂喹啉环衍生物
WO2024249983A1 (en) * 2023-06-02 2024-12-05 Westol, Llc 2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
KR102732584B1 (ko) 2024-03-28 2024-11-21 (주)신한티이씨 전기 배전반의 화재 위험 감지 및 진압용 소화 장치

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
NL7800191A (nl) 1977-01-10 1978-07-12 Ciba Geigy Anthelmintisch preparaat.
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ503079A (en) 1997-08-28 2002-07-26 Nissan Chemical Ind Ltd Cyanoacrylate-containing antibacterial and antifungal agents, algicides and antifouling agents
EP1097158B1 (en) 1998-07-10 2006-01-25 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
WO2000018740A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
KR100951499B1 (ko) 2002-03-20 2010-04-07 브리스톨-마이어스 스큅 컴퍼니 플루오로옥신돌의 포스페이트 전구약물
MXPA05009359A (es) 2003-03-03 2005-11-04 Hoffmann La Roche Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
JP2007502819A (ja) 2003-08-19 2007-02-15 ワイス・ホールディングズ・コーポレイション ４−アミノ−３−キノリンカルボニトリルの調製方法
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1881981A1 (en) 2005-05-18 2008-01-30 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
CA2608540A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
KR20080067361A (ko) 2005-10-28 2008-07-18 아보트 러보러터리즈 Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
ES2481442T3 (es) 2006-11-09 2014-07-30 Probiodrug Ag Inhibidores novedosos de glutaminil ciclasa
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
CA2802130C (en) * 2010-06-09 2014-09-09 Tianjin Hemay Bio-Tech Co., Ltd Cyanoquinoline derivatives
EP2708540B1 (en) 2011-05-10 2018-07-25 Kyowa Hakko Kirin Co., Ltd. Pyrimido-diazepinone compound
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9522914B2 (en) 2011-10-27 2016-12-20 Taisho Pharmaceutical Co., Ltd Azole derivative
KR102033806B1 (ko) 2011-11-11 2019-10-17 길리어드 아폴로, 엘엘씨 Ａｃｃ 억제제 및 이의 용도
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
IN2015DN03795A (el) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
CA2932039A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
WO2016007966A2 (en) * 2014-07-11 2016-01-14 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
BR112017005693A2 (pt) 2014-09-24 2017-12-12 Gilead Sciences Inc método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
TWI685491B (zh) 2014-12-23 2020-02-21 美商基利科學股份有限公司 製備５-（４-環丙基-１ｈ-咪唑-１-基）-ｎ-（６-（４-異丙基-４ｈ-１,２,４-三唑-３-基）吡啶-２-基）-２-氟-４-甲基苯甲醯胺之方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EA201892625A1 (ru) 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
CN107111844B (zh) 2015-01-16 2021-07-13 3M创新有限公司 用于选择网格动作以改善网格结果的系统和方法
JP6525362B2 (ja) * 2015-07-06 2019-06-05 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔモジュレーターとしての６−アミノ−キノリン−３−カルボニトリル
ME03425B (me) 2015-07-06 2020-01-20 Gilead Sciences Inc Cot modulatori i postupci za njihovu upotrebu
EP3398598B1 (en) 2015-12-31 2022-04-06 Hitgen Inc. Sulfonamide derivative and preparation method and use thereof
CA3172549A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
EP3473715B1 (en) 2016-06-21 2021-08-04 PHC Holdings Corporation Catalase inhibitor and method for measuring analyte using catalase inhibitor
WO2018005435A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
ES2963841T3 (es) 2017-03-03 2024-04-02 Gilead Sciences Inc Procesos para preparar inhibidores de ACC y formas sólidas del mismo
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
AU2018250614A1 (en) 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
KR20220103807A (ko) 2017-10-06 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
EP3934615A4 (en) 2019-03-08 2023-01-25 The Regents Of The University Of California ACNE TREATMENT COMPOSITIONS AND METHODS
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
KR20220161438A (ko) 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
KR20220160645A (ko) 2020-04-02 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 저해제 화합물의 제조 방법
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法

Also Published As

Publication number Publication date
SI3191470T1 (sl) 2019-04-30
PT3456717T (pt) 2021-05-26
EA036788B1 (ru) 2020-12-21
JP2019178178A (ja) 2019-10-17
JP6781221B2 (ja) 2020-11-04
US20190248807A1 (en) 2019-08-15
SMT201900244T1 (it) 2019-05-10
MX370984B (es) 2020-01-09
EP3456717A1 (en) 2019-03-20
AU2024204902A1 (en) 2024-08-01
PT3191470T (pt) 2019-06-05
NZ750707A (en) 2023-09-29
CN119143730A (zh) 2024-12-17
ME03425B (me) 2020-01-20
KR102443575B1 (ko) 2022-09-16
UA123010C2 (uk) 2021-02-03
MX2017004737A (es) 2017-06-19
US11905299B2 (en) 2024-02-20
TW201908305A (zh) 2019-03-01
TW201712005A (zh) 2017-04-01
KR20200013120A (ko) 2020-02-05
JP2018193405A (ja) 2018-12-06
NZ738525A (en) 2019-03-29
EP3191470B1 (en) 2019-02-27
PH12018500031B1 (en) 2018-07-09
BR102016015656A2 (pt) 2020-09-24
IL266995B (en) 2020-05-31
DK3191470T3 (en) 2019-04-15
AU2022204050B2 (en) 2024-04-18
CL2017003356A1 (es) 2018-07-06
CA2971640C (en) 2020-09-22
PL3191470T3 (pl) 2019-08-30
AU2022204050A1 (en) 2022-06-30
UY36771A (es) 2017-01-31
IL256433A (en) 2018-02-28
AU2016290820B2 (en) 2019-03-07
JP2024100865A (ja) 2024-07-26
PH12018500031A1 (en) 2018-07-09
JP7138155B2 (ja) 2022-09-15
US11066414B2 (en) 2021-07-20
SG11201702041PA (en) 2017-04-27
TWI634112B (zh) 2018-09-01
KR20240008398A (ko) 2024-01-18
CN107922390B (zh) 2019-05-10
EP3896064A1 (en) 2021-10-20
HUE043310T2 (hu) 2019-08-28
IL293770B2 (en) 2023-07-01
PH12020551397A1 (en) 2021-08-16
ECSP17084635A (es) 2018-01-31
SV2017005605A (es) 2018-07-18
US20170152240A1 (en) 2017-06-01
PE20180462A1 (es) 2018-03-06
WO2017007689A1 (en) 2017-01-12
EA201792613A1 (ru) 2018-06-29
AU2019203122B2 (en) 2020-10-01
EP3456717B1 (en) 2021-03-17
MY196173A (en) 2023-03-17
CN114380799A (zh) 2022-04-22
JP2021042252A (ja) 2021-03-18
CA2971640A1 (en) 2017-01-12
AU2020257055B2 (en) 2022-03-31
KR20220129667A (ko) 2022-09-23
ES2734713T3 (es) 2019-12-11
JP6430060B2 (ja) 2018-11-28
JP2018520161A (ja) 2018-07-26
SI3456717T1 (sl) 2021-08-31
IL266995A (en) 2019-07-31
AU2020257055A1 (en) 2020-11-12
MA39422A (fr) 2017-07-19
US20240254137A1 (en) 2024-08-01
LT3191470T (lt) 2019-05-10
ES2872076T3 (es) 2021-11-02
US20230002407A1 (en) 2023-01-05
JP6906021B2 (ja) 2021-07-21
TW202114673A (zh) 2021-04-16
PL3456717T3 (pl) 2021-10-25
HRP20190853T1 (hr) 2019-06-28
KR20180022982A (ko) 2018-03-06
IL293770A (en) 2022-08-01
KR102073641B1 (ko) 2020-02-05
TWI748539B (zh) 2021-12-01
CN114380799B (zh) 2024-10-01
US20170008905A1 (en) 2017-01-12
CO2017013351A2 (es) 2018-05-21
IL293770B1 (en) 2023-03-01
KR101974793B1 (ko) 2019-05-02
DOP2017000311A (es) 2018-01-15
RS58639B1 (sr) 2019-05-31
CN109879859A (zh) 2019-06-14
US20200123172A1 (en) 2020-04-23
SA517381350B1 (ar) 2021-03-11
US20180237455A1 (en) 2018-08-23
IL274568B (en) 2022-07-01
KR20190045416A (ko) 2019-05-02
MA39422B1 (fr) 2019-03-29
EP3191470A1 (en) 2017-07-19
US9878995B2 (en) 2018-01-30
CR20170599A (es) 2018-02-28
IL274568A (en) 2020-06-30
JP2022082816A (ja) 2022-06-02
AU2016290820A1 (en) 2018-01-18
CN109879859B (zh) 2022-01-25
CN107922390A (zh) 2018-04-17
BR102016015656B1 (pt) 2021-11-03
TWI699361B (zh) 2020-07-21
CU20170172A7 (es) 2018-06-05
AU2019203122A1 (en) 2019-05-30
IL256433B (en) 2019-06-30

Similar Documents

Publication Publication Date Title
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2023001910A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CY1120481T1 (el) Kv1.3 ανταγωνιστες και μεθοδοι χρησης
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
MX2023006416A (es) Anticuerpos, usos y metodos.
CY1122822T1 (el) Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο
BR112016027455A2 (pt) moduladores ppar
GT201500225A (es) Proceso para producir compuesto de piridazinona y producciond e sus intermediarios
MX2016009696A (es) Formulaciones de antibióticos tópicas..
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
UA104973U (uk) Біологічно активна добавка шумілова
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin